Concepedia

Author

S. Xiong

Gilead Sciences (United States)ORCID

Also Known As

S Xiong, S. Xiong, Shengfeng Xiong, Shi-Ying Xiong, Shi‐Ying Xiong, Sujie Xiong

24

Publications

808

Citations

8

H-Index

25

Concepts

All Affiliations

Gilead Sciences (United States)
SX

About

S. Xiong is an author at Gilead Sciences (United States) specializing in medicine, viral hepatitis, and hepatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

190

2

Engineering

1

1

22

3

Public Health

1

1

44

4

Biomolecular Engineering

1

1

22

5

Epidemiology

1

1

44

S. Xiong

×

6

Publications

743

Citations

6

H-Index

YearCitations

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Marion G. Peters, Hie‐Won Hann, Paul Martin,

Gastroenterology

2003

553

Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients

C. Westland, Hao Yang, William E. Delaney,

Journal of Viral Hepatitis

2005

67

57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

Xiaole Qi, A. Snow, Vincent Thibault,

Journal of Hepatology

2004

44

Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

S. Xiong, Hongu Yang, C. Westland,

Journal of Hepatology

2003

41

382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase

Hao Yang, Xiaole Qi, Kalyan Das,

Journal of Hepatology

2004

22

Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients

Eugene R. Schiff, P. Neuhaus, Hans L. Tillman,

Journal of Hepatology

2002

16

Page 1